Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Haskelberg, Hila ^a   Hoy, Jennifer F ^b   Amin, Janaki ^a   Ebeling, Peter R ^c   Emery, Sean ^a   Carr, Andrew ^d   Allworth, Anthony ^e   Anderson, Jonathan ^e   Baker, David ^e   Bloch, Mark ^e   Boyd, Mark ^e   Chuah, John ^e   Cooper, David ^e   Davies, Stephen ^e   Dayan, Linda ^e   Donohue, William ^e   Doong, Nicholas ^e   Dwyer, Dominic ^e   Dyer, John ^e   Finlayson, Robert ^e   Giles, Michelle ^e   Gordon, David ^e   Kelly, Mark ^e   Medland, Nicholas ^e   Moore, Richard ^e   Nolan, David ^e   Orth, David ^e   Post, Jeffrey ^e   Quin, John ^e   Read, Tim ^e   Roth, Norman ^e   Russell, Darren ^e   Shaw, David ^e   Smith, David ^e   Smith, Don ^e   Street, Alan ^e   Tee, Ban Kiem ^e   Woolley, Ian ^e   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALKALINE PHOSPHATASE BONE ISOENZYME; COLLAGEN; CYTOKINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; TYPE 1 COLLAGEN CARBOXY TERMINAL CROSS LINKING TELOPEPTIDE; UNCLASSIFIED DRUG;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT MASS; FEMALE; FRACTURE RISK; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; SIGNAL TRANSDUCTION; SPINE;

ABSORPTIOMETRY, PHOTON; ADENINE; ADULT; BONE DENSITY; BONE REMODELING; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84862490997     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038377     Document Type: Article

References (33)

1. Brown TT, Qaqish RB, (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20: 2165-2174.
2. Triant VA, Brown TT, Lee H, Grinspoon SK, (2008) Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 93: 3499-3504.
3. Mallon PWG, (2010) HIV and bone mineral density. Current Opinion in Infectious Diseases 23: 1-8.
4. Bolland MJ, Wang TK, Grey A, Gamble GD, Reid IR, (2011) Stable Bone Density in HAART-Treated Individuals with HIV: A Meta-Analysis. J Clin Endocrinol Metab 96: 2721-2731.
5. Arlot ME, Sornay-Rendu E, Garnero P, Vey-Marty B, Delmas PD, (1997) Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res 12: 683-690.
6. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191-201.
7. Stellbrink H-J, Orkin C, Arribas JR, Compston J, Gerstoft J, et al. (2010) Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clinical Infectious Diseases 51: 963-972.
8. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, et al. (2011) Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: aids clinical trials group A5224s, a substudy of ACTG A5202. J Infect Dis 203: 1791-1801.
9. Garnero P, Hausherr E, Chapuy M-C, Marcelli C, Grandjean H, et al. (1996) Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. Journal of Bone and Mineral Research 11: 1531-1538.
10. Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA (2005) Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study. J Bone Miner Res 20: 579-587.
11. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, et al. (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22: 391-420.
12. Yun AJ, Lee PY, (2004) Maldaptation of the link between inflammation and bone turnover may be a key determinant of osteoporosis. Med Hypotheses 63: 532-537.
13. Ding C, Parameswaran V, Udayan R, Burgess J, Jones G, (2008) Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab 93: 1952-1958.
14. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, et al. (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 201: 1788-1795.
15. Piso RJ, Rothen M, Rothen JP, Stahl M, (2011) Markers of Bone Turnover Are Elevated in Patients With Antiretroviral Treatment Independent of the Substance Used. JAIDS Journal of Acquired Immune Deficiency Syndromes 56: 320.
16. Yin MT, Lu D, Cremers S, Tien PC, Cohen MH, et al. (2010) Short-term bone loss in HIV-infected premenopausal women. Journal of Acquired Immune Deficiency Syndromes: JAIDS 53: 202-208.
17. Aukrust P, Haug CJ, Ueland T, Lien E, Muller F, et al. (1999) Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 84: 145-150.
18. Ofotokun I, Weitzmann N, Vunnava A, Sheth A, Villinger F, et al. (2011) HAART-induced Immune Reconstitution: A Driving Force Behind Bone Resorption in HIV/AIDS. 18th Conference on Retroviruses and Opportunistic Infections (CROI). Boston.
19. van Vonderen MG, Mallon P, Murray B, Doran P, Agtmael Mv, et al. (2011) Changes in Bone Biomarkers in ARV-naïve HIV+ Men Randomized to NVP/LPV/r or AZT/3TC/LPV/r Help Explain Limited Loss of Bone Mineral Density over the First 12 Months after ART Initiation 18th Conference on Retroviruses and Opportunistic Infections (CROI). Boston.
20. Martin A, Bloch M, Amin J, Baker D, Cooper DA, et al. (2009) Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clinical Infectious Diseases 49: 1591.
21. FRAX: WHO fracture risk assessment tool. Available:http://www.shef.ac.uk/FRAX/. Accessed: 2011 Apr 14.
22. NOF: Clinician's Guide to Prevention and Treatment of Osteoporosis. Available:http://www.nof.org/professionals/clinical-guidelines. Accessed: 2011 Apr 14.
23. World Health Organization (2004) WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. WHO.
24. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, et al. (2009) Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 23: 817-824.
25. Borderi M, Gibellini D, Vescini F, De Crignis E, Cimatti L, et al. (2009) Metabolic bone disease in HIV infection. AIDS 23: 1297-1310.
26. Malizia AP, Cotter E, Chew N, Powderly WG, Doran PP, (2007) HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. AIDS Res Hum Retroviruses 23: 243-250.
27. Grigsby IF, Pham L, Gopalakrishnan R, Mansky LM, Mansky KC, (2010) Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts. Biochem Biophys Res Commun 391: 1324-1329.
28. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Carlson AE, et al. (2010) Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochemical & Biophysical Research Communications 394: 48-53.
29. Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, et al. (2011) Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco. PLoS One 6: e23688.
30. Schulte CM, Beelen DW, (2004) Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. Blood 103: 3635-3643.
31. Rosen CJ, Klibanski A, (2009) Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. The American Journal of Medicine 122: 409-414.
32. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, et al. (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clinical Infectious Diseases 36: 482-490.
33. Dolan SE, Carpenter S, Grinspoon S, (2007) Effects of weight, body composition, and testosterone on bone mineral density in HIV-infected women. Journal of Acquired Immune Deficiency Syndromes: JAIDS 45: 161-167.